全文获取类型
收费全文 | 2360883篇 |
免费 | 198246篇 |
国内免费 | 4206篇 |
专业分类
耳鼻咽喉 | 34340篇 |
儿科学 | 72591篇 |
妇产科学 | 62969篇 |
基础医学 | 332680篇 |
口腔科学 | 67542篇 |
临床医学 | 214595篇 |
内科学 | 465082篇 |
皮肤病学 | 47984篇 |
神经病学 | 199382篇 |
特种医学 | 95966篇 |
外国民族医学 | 886篇 |
外科学 | 360000篇 |
综合类 | 56159篇 |
现状与发展 | 1篇 |
一般理论 | 977篇 |
预防医学 | 189236篇 |
眼科学 | 55513篇 |
药学 | 177329篇 |
4篇 | |
中国医学 | 4262篇 |
肿瘤学 | 125837篇 |
出版年
2018年 | 24271篇 |
2016年 | 20651篇 |
2015年 | 23356篇 |
2014年 | 33635篇 |
2013年 | 50938篇 |
2012年 | 68897篇 |
2011年 | 72466篇 |
2010年 | 42591篇 |
2009年 | 40950篇 |
2008年 | 68920篇 |
2007年 | 73277篇 |
2006年 | 74179篇 |
2005年 | 72226篇 |
2004年 | 69504篇 |
2003年 | 67102篇 |
2002年 | 66274篇 |
2001年 | 112466篇 |
2000年 | 116372篇 |
1999年 | 97820篇 |
1998年 | 26205篇 |
1997年 | 23825篇 |
1996年 | 23787篇 |
1995年 | 24480篇 |
1994年 | 23051篇 |
1993年 | 21458篇 |
1992年 | 79360篇 |
1991年 | 76469篇 |
1990年 | 73602篇 |
1989年 | 70865篇 |
1988年 | 65827篇 |
1987年 | 64817篇 |
1986年 | 61354篇 |
1985年 | 58411篇 |
1984年 | 44186篇 |
1983年 | 37571篇 |
1982年 | 22807篇 |
1981年 | 20237篇 |
1980年 | 18946篇 |
1979年 | 41256篇 |
1978年 | 28922篇 |
1977年 | 24267篇 |
1976年 | 22773篇 |
1975年 | 23911篇 |
1974年 | 29587篇 |
1973年 | 28010篇 |
1972年 | 26208篇 |
1971年 | 24147篇 |
1970年 | 22731篇 |
1969年 | 21075篇 |
1968年 | 19138篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
41.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
42.
Melanie Y. T. Chan Arbab Anwar William J. S. Lockley 《Journal of labelled compounds & radiopharmaceuticals》2022,65(4):101-111
Base catalysed exchange with sodium hydroxide, calcium oxide or N,N,N,N-tetramethylguanidine in deuterium oxide is a viable procedure for the preparation of terminally deuterated alkynes for those alkynes stable to strong base. The use of silver perchlorate as a catalyst is an alternative practical option when labelling alkynes which are sensitive to base or contain functionalities which would lead to labelling elsewhere in the molecule. Labelling with this catalyst takes place smoothly at ambient temperature in a mixture of N,N-dimethylformamide and deuterium oxide. 相似文献
43.
44.
45.
46.
Keith B. Diamond Ivan J. Golub Asad M. Ashraf Samuel J. Swiggett Paul V. Romeo Jack Choueka 《Seminars in Arthroplasty》2022,32(1):15-22
BackgroundWhile studies have demonstrated favorable outcomes in utilization of primary total shoulder arthroplasty (TSA) for the treatment of glenohumeral osteoarthritis (OA), adverse events such as infections can still occur. Periprosthetic joint infections (PJIs) are associated with worse outcomes and patient morbidity. The purpose of this study was to: (1) compare patient demographics amongst TSA patients with and without PJIs following primary TSA; and (2) identify patient-related risk factors for PJIs following primary TSA.MethodsPatients undergoing primary TSA for the treatment of glenohumeral OA were identified using the Mariner administrative claims database by CPT code 23,472. Laterality modifiers were utilized to ensure PJIs were developing in the correct laterality as those patients undergoing primary TSA. Inclusion for the study group consisted of patients who developed PJIs within 2-years after the index procedure, whereas patients who did not develop PJIs served as the comparison cohort. Primary outcomes analyzed included patient demographics and patient-related risk factors for PJIs following primary TSA. A stepwise backwards elimination multivariate binomial logistic regression analyses was performed to determine the odds (OR) of PJIs in patients undergoing primary TSA. A P value less than .05 was considered statistically significant.ResultsThe query yielded 15,396 patients who underwent primary TSA for glenohumeral OA, of which 191 patients developed PJIs and 15,205 did not develop PJIs. The study found statistically significant differences amongst patients who did and did not develop PJIs following primary TSA with respect to age, sex, and presence of comorbid conditions. Risk factors associated with developing PJIs following primary TSA included: pathologic weight loss (OR: 2.06, P < .0001), obesity (OR: 1.56, P = .0001), male sex (OR: 1.52, P = .007), and peripheral vascular disease (OR: 1.46, P = .022).ConclusionAs the number of primary TSAs for the treatment of glenohumeral OA increase worldwide, identifying modifiable risk-factors to reduce the incidence of infection is critical. The study found various modifiable and non-modifiable risk factors associated with developing PJIs following primary TSA. This study is valuable to orthopedists in order to identify and risk-stratify patients with regard to PJI in the setting of primary TSA for OA.Level of EvidenceLevel III; Case-Control Study 相似文献
47.
48.
In 2019, the scientists who discovered how cells sense and adapt to oxygen availability were awarded the Nobel Prize. This elegant sensing pathway is conserved throughout evolution, and it underpins the physiology and pathology that we, as clinicians in anaesthesia and critical care, encounter on a daily basis. The purpose of this review is to bring hypoxia-inducible factor, and the oxygen-sensing pathway as a whole, to the wider clinical community. We describe how this unifying mechanism was discovered, and how it orchestrates diverse changes such as erythropoiesis, ventilatory acclimatisation, pulmonary vascular remodelling and altered metabolism. We explore the lessons learnt from genetic disorders of oxygen sensing, and the wider implications in evolution of all animal species, including our own. Finally, we explain how this pathway is relevant to our clinical practice, and how it is being manipulated in new treatments for conditions such as cancer, anaemia and pulmonary hypertension. 相似文献
49.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
50.
Deshmukh Abhishek J. DeSimone Christopher V. 《Journal of interventional cardiac electrophysiology》2022,65(1):263-265
Journal of Interventional Cardiac Electrophysiology - 相似文献